论文部分内容阅读
为探讨甲胎蛋白（AFP）和血清肝癌特异蛋白（SHCSP）对肝细胞癌（HCC）的诊断价值，对56例健康对照、82例肝炎患者、89例原发性肝癌、26例继发性肝癌患者进行了血清AFP和SHCSP联合检测。AFP采用单克隆抗体酶无法，阳性＞400ng／mL；SHCSP采用醋酸纤维薄膜点样显色法，点样标记显紫红色为阳性。检测结果：健康组、肝炎组、原发性肝癌组、继发性肝癌组的AFP阳性率分别为0％、9．76％、57．30％、61．54％，SHCSP阳性率分别为0％、1．22％、92．13％、92．13％、显示SHCSP诊断HCC较AFP有较高的敏感性和较强的特异性。二种方法联检，可弥补AFP阳性率低和SHCSP受重症黄殖干扰的缺点，提高HCC检测符合率，减少HCC的漏诊和误诊。
To investigate the diagnostic value of alpha fetoprotein (AFP) and serum hepatoma specific protein (SHCSP) for hepatocellular carcinoma (HCC), 56 healthy controls, 82 hepatitis patients, 89 primary liver cancers, and 26 secondary cancers Patients with hepatocellular carcinoma were tested for combined AFP and SHCSP. AFP using monoclonal antibody enzyme can not, positive> 400ng/mL; SHCSP using acetate fiber film spot coloring method, spot marker marked purple red is positive. Test results: The positive rate of AFP in healthy group, hepatitis group, primary liver cancer group and secondary liver cancer group were 0%, 9.76%, 57.30%, 61.54%, and the positive rate of SHCSP was 0 %,1.22%,92.13%,92.13% showed that SHCSP has higher sensitivity and stronger specificity than AFP in the diagnosis of HCC. The two methods combined to compensate for the shortcomings of AFP positive rate and SHCSP interfered with severe yellow colony, improve the HCC detection coincidence rate, reduce the missed diagnosis and misdiagnosis of HCC.